Category:

More than 450 patients died prematurely in a British hospital after they were given powerful painkillers with no medical justification, in what a damning report on Wednesday found was a “disregard for human life”...Britain’s prosecution service said it would examine whether criminal charges could be brought following the deaths at Gosport War Memorial Hospital in southern England...An independent panel found that between 1989 and 2000, there was an institutionalized regime of prescribing and administering dangerous doses of opioids at the hospital which were not clinically necessary...“There was a disregard for human life and a culture of shortening the lives of a large number of patients,” the report said, adding that warnings from nurses had been ignored and there had been a failure by police and medical regulators to protect patients.

Kentucky has sued Walgreens for its role in the state's opioid epidemic...Attorney General Andy Beshear filed the suit against Walgreens for its dual role as a distributor and a pharmacy, saying it allegedly failed to monitor its own operations and shipped and dispensed large amounts of opioids...The lawsuit alleges "unfair, misleading and deceptive business practices by Walgreens for excessively distributing and dispensing opioids in Kentucky and for failing to legally report to state and federal authorities the suspiciously large orders it received for prescription opioids."...This is the sixth opioid-related suit Beshear has filed. He's sued three drug distributors, AmerisourceBergen, which Walgreens Boots Alliance owns a roughly 26 percent stake in, McKesson and Cardinal Health. He's also sued pharmaceutical manufacturers, including Johnson & Johnson.

Kelly Davio, welcome to This Week in Managed Care from the Managed Markets News Network

The National Institutes of Health is explaining how it will spend $500 million in research funds Congress appropriated to address the current opioid crisis...The list of objectives, published...in the Journal of the American Medical Association, includes: developing new medications to treat opioid addiction; tinkering with existing medications so they can be taken less often; improving medicines that reverse overdoses; developing new models of caring for people with opioid addiction in the healthcare and criminal justice systems; determining the best way to care for newborns in opioid withdrawal; discovering and validating new targets for non-addictive pain drugs and devices, and partnering with pharmaceutical companies to accelerate new pain and addiction medications. The $500 million will be distributed as research grants after a call for proposals later this summer.

Dozier's death warrant was signed by Clark County District Court Judge Jennifer Togliatti, who last November blocked the execution over concerns that one drug in the three-drug protocol would immobilize the inmate and mask any signs of pain and suffering. The warrant didn't address her previous concerns..."The (state) Supreme Court never decided whether Mr. Dozier would experience extreme pain, or if he would suffocate to death, or if this protocol is constitutionally adequate," ACLU legal director Amy Rose said Wednesday. She conceded that her group didn't have legal standing to act on Dozier's behalf unless he asks for it...Dozier, 47, has said he wants to die and doesn't really care if he experiences pain. But he did let a team of federal public defenders challenge the drugs and method that Nevada prison officials planned to use...Nevada and other states have struggled in recent years to find drugs after pharmaceutical companies and distributors banned their use for executions...

If you need to get rid of old or expired medication, there are now 11 local Walgreens where you can get the chore done...The company opened its 1,000th medication disposal kiosk in the nation...4905 W. Tropicana Ave. in Las Vegas. The steel-box kiosks in Walgreens pharmacies are open during store hours for people to drop off unused pills for free, ensuring that the active ingredients don’t get into Nevada’s landfills or sewage systems...Gov. Brian Sandoval, who was on hand for the kiosk unveiling, said the disposal boxes also will help curb Nevada’s opioid crisis by keeping the drug out of the wrong hands...There are 12 kiosks located in Nevada: one in Henderson, nine in Las Vegas, one in North Las Vegas and one in Reno...Richard Ashworth, Walgreens president of operations, said the kiosks across the U.S. have already collected more than 270 tons of medications since the program began in 2016. The company plans to open 500 more kiosks...

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

The Food and Drug Administration has published a statement from its commissioner Scott Gottlieb proposing a new reimbursement model for antibiotics and antimicrobials, which it believes will help achieve associated public health goals and overcome investment challenges...The FDA’s idea is that instead of hospitals being reimbursed for antimicrobials on a per-use, which it claims is hindering research and development in the field, they will be reimbursed for licences for certain antimicrobials drugs that target multi-drug resistant infections...The FDA believes this model will help to achieve public health goals because it would ‘create a natural market for drugs that meet certain public health criteria, by providing a predictable return on investment and revenue stream through more foreseeable licensing fees’ and ‘it would put the institutions fully in charge of stewardship of these important medicines. Once they purchase the ability to access a drug, they would be stewards of its use up to a certain number of annual doses’...the proposal would address investment challenges faced by producers of antimicrobials that target multi-drug resistant organisms because it may offer a ‘pull incentive’ that can create a predictable market for antimicrobials with a narrow set of public health applications. In addition, it could disconnect return on investment on these drugs from the volume of the drug that is used...

A grand jury has indicted CEO Elizabeth Holmes and...Sunny Balwani for alleged fraud at Theranos, the disgraced Silicon Valley company that once promised to revolutionize blood testing in a pitch that was too good to be true...The criminal charges filed by federal prosecutors allege that Holmes and Balwani bilked investors out of hundreds of millions of dollars while also defrauding doctors and patients through years of lies that put thousands of people in personal danger...(they) are charged with two counts of conspiracy to commit wire fraud and nine counts of wire fraud in the indictment, which was handed down on Thursday and unsealed on Friday. They now each face a maximum of 20 years in prison and up to $2.7 million in fines, a figure that doesn’t include any cash the government might demand as restitution for the alleged fraud...Holmes and Balwani lied brazenly about their technology’s capabilities — even though they knew it was inaccurate, unreliable, slow, and limited in terms of the tests it could perform...They marketed their blood test sold in Walgreens stores to consumers in Arizona and California, the indictment says, even though they knew it could not consistently report accurate levels of calcium, chloride, and potassium, among other medical tests. They told investors that they were using their own proprietary machines to test patients’ blood, when in fact they were using commercially available analyzers they’d purchased...

...Pfizer has won its appeal in the UK’s Competition Appeals Tribunal against a £84.2m ($111.6m) fine imposed by the Competition and Markets Authority for dramatically increasing the price of its epilepsy drug, Epanutin...Following a three year investigation, the CMA ruled in 2016 Pfizer and its distributor Flynn Pharma had abused their dominant market position by raising the price of Epanutin from £2.83 per pack of capsules to £67.50, which represents more than a 2,000% increase. Annual NHS spending on the drug increased from £2m in 2012 to £50m in 2013...Philip Marsden, the CMA’s chairman...said the companies had “deliberately exploited” the generic product loophole that allowed the price increase...“Businesses are generally free to set prices as they see fit but those holding a dominant position should not abuse this situation and set prices that are excessive and unfair. There is no justification for such rises when phenytoin sodium capsules are a very old drug for which there has been no recent innovation or significant investment.”...The CTA declared that...CMA had not applied the correct legal tests to assess whether the price rise was excessive and had failed to consider the correct price for the product and take into account other comparable products